Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Possible Effect of Microrna-155 (Mir-155) and Bace1 Inhibitors in the Memory of Patients With Down Syndrome and Alzheimer's Disease: Design, Synthesis, Virtual Screening, Molecular Modeling and Biological Evaluations Publisher Pubmed



Mahernia S1 ; Hassanzadeh M2 ; Adib M3 ; Peytam F3 ; Haghighijoo Z4 ; Iraji A4 ; Mahdavi M5 ; Edraki N4 ; Amanlou M1, 2, 6
Authors
Show Affiliations
Authors Affiliations
  1. 1. The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. School of Chemistry, College of Science, University of Tehran, Tehran, Iran
  4. 4. Medicinal and Natural Products Chemistry Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  5. 5. Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran

Source: Journal of Biomolecular Structure and Dynamics Published:2022


Abstract

MiR-155 plays main roles in several physiological and pathological mechanisms, such as Down syndrome (DS), immunity and inflammation and potential anti-AD therapeutic target. The miR-155 is one of the overexpressed miRNAs in DS patients that contribute directly and indirectly to the onset or progression of the DS. Since the miR-155 can simultaneously reduce the translation of several genes at post-transcriptional levels, targeting the miR-155 might set the stage for the treatment of DS. One of the rational strategies in providing therapeutic interventions in this respect is to design and develop novel small molecules inhibiting the miR-155 function or biogenesis or maturation. In the present study, we aim to introduce small molecule compounds with the potential to inhibit the generation of the selectively miR-155 processing by employing computational drug design approaches, as well as in vitro studies. We designed and synthesized a novel series of imidazo[1,2-a]pyridines derivatives as new nonpeptic candidates for the treatment of DS with AD. The designed compounds were investigated for their BACE1 and miR-155 binder inhibitory potential in vitro and in cell. In addition, we present a systematic computational approach that includes 3 D modeling, docking-based virtual screening, and molecular dynamics simulation to identify Small - molecule inhibitors of pre-miR-155 maturation. To confirm the inhibitory potential of compound 8k on miR-155 maturation, qRT- PCR was performed. All our results confirm that compound 8k, in addition to being a good inhibitor of BACE1, can also be a good inhibitor of miR-155. Communicated by Ramaswamy H. Sarma. © 2021 Informa UK Limited, trading as Taylor & Francis Group.
Other Related Docs
15. Non-Coding Rnas and Exosomal Non-Coding Rnas in Pituitary Adenoma, Pathology Research and Practice (2023)
16. Micrornas and Long Non-Coding Rnas As Biomarkers for Polycystic Ovary Syndrome, Journal of Cellular and Molecular Medicine (2022)
32. Exosomes and Micrornas in Biomedical Science, Synthesis Lectures on Biomedical Engineering (2022)
34. Tumor Suppressive Function of Microrna-192 in Acute Lymphoblastic Leukemia, Bosnian Journal of Basic Medical Sciences (2017)
36. Epigenetic-Based Cancer Therapeutics: New Potential Hdac8 Inhibitors, Journal of Biomolecular Structure and Dynamics (2022)
40. Exosomal Micrornas in Regulation of Tumor Cells Resistance to Apoptosis, Biochemistry and Biophysics Reports (2024)